Patient 2 (Pt #2) was a 50-years-old woman diagnosed with de novo AML due to 50% of myeloid blast cells documented at diagnostic BM evaluation, expression of CD34+, CD117+, CD33+, CD13+, HLA-DR+, CD4+, and CD25+ immunophenotypic markers, NK by chromosome banding analysis, an FLT3-ITD (allelic ratio, AR = 0.8), and an NPM1 mutation (NPM1mut/ABL × 100 = 262.16 by real-time RT-PCR) at conventional molecular analysis. This evidence concerns the gene CD4 and acute myeloid leukemia.